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Introduction: Insulin analogues are structurally modified molecules with altered pharmaco-kinetic and -dynamic
properties compared to regular human insulin used by diabetic patients. While these compounds are tested for
undesired mitogenic effects, an epidemiological discussion is ongoing regarding an association between insulin
analogue therapy and increased cancer incidence, including breast cancer. Standard in vivo rodent carcinogenesis
assays do not pick up this possible increased carcinogenic potential.
Methods: Here we studied the role of insulin analogues in breast cancer development. For this we used the
human relevant mammary gland specific p53R270H/+WAPCre mouse model. Animals received life long repeated
treatment with four different insulin (−like) molecules: normal insulin, insulin glargine, insulin X10 (AspB10) or
insulin-like growth factor 1 (IGF1).
Results: Insulin-like molecules with strong mitogenic signaling, insulin X10 and IGF1, significantly decreased the
time for tumor development. Yet, insulin glargine and normal insulin, did not significantly decrease the latency time
for (mammary gland) tumor development. The majority of tumors had an epithelial to mesenchymal transition
phenotype (EMT), irrespective of treatment condition. Enhanced extracellular signaling related kinase (Erk) or
serine/threonine kinase (Akt) mitogenic signaling was in particular present in tumors from the insulin X10 and IGF1
treatment groups.
Conclusions: These data indicate that insulin-like molecules with enhanced mitogenic signaling increase the risk of
breast cancer development. Moreover, the use of a tissue specific cancer model, like the p53R270H/+WAPCre mouse
model, is relevant to assess the intrinsic pro-carcinogenic potential of mitogenic and non-mitogenic biologicals such
as insulin analogues.Introduction
For two decades there has been an intensive debate
about the human risk for increased cancer incidence
when using insulin analogues [1]. Insulin and insulin an-
alogues act via the insulin receptor (IR), of which there
are two isoforms, IRA and IRB, and to a lesser extent via
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unless otherwise stated.increased residence time as well as an increased binding
affinity of synthetic insulin-like molecules towards IRA
and especially IGF1R might affect carcinogenesis [2,3].
Downstream signaling via these insulin receptor family
members occurs via distinct pathways. Upon stimulation
with insulin analogues with high affinity for IRB the
PI3K/Akt pathway is activated, which is related to the
metabolic role of insulin [4]. In contrast, activation of
the IGF1 pathway via IGF1R results in an upregulation
of both the MAPK/Erk signaling cascade and an asym-
metrical activation of the Akt pathway [5], which is dir-
ectly related to the limited mitogenic effect of insulin.
Stimulation of the IRA results in a downstream signaling
cascade similar to that observed after IGF1R activational. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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between expression levels of both IGF1 and its receptor
(IGF1R) and cancer initiation/progression [6,7]. This cre-
ates a situation whereby insulin analogues with increased
affinity for IRA and/or IGF1R may increase the cancer
hazard.
Current approaches to assess the intrinsic carcino-
genic potential of insulin analogues are limited. The
binding affinity of insulin analogues to both IR and
IGF1R and their subsequent activation and overall
mitogenic capacity are currently used as part of the risk
assessment in terms of carcinogenic potential of newly
developed insulin analogues. This in vitro assessment is
limited by the variability in the cell lines, culture condi-
tions and proliferation assays that are used [8,9]. Fur-
thermore, kinetic parameters, such as administration,
distribution, metabolism and excretion, cannot always
be captured in these in vitro models. Some insulin ana-
logues that are currently on the market have also been
tested in two-year carcinogenicity studies in rats and/or
mice [10,11]. So far only insulin X10 (also called
AspB10) has been indicated to increase the tumor inci-
dence in the chronic rodent studies and, consequently, it
never reached the market [1,10,11]. While most insulin
analogues, including glargine [12-14], were negative in
these chronic bioassays, several epidemiological studies
showed an increased breast cancer risk [15-18], which
could not be observed by others [19-26]. Altogether these
data stirred concerns that growth factor-like insulin ana-
logues are potential non-genotoxic carcinogens [27].
Genetically engineered mouse (GEM) cancer models
constitute powerful, alternative methods to assess the
carcinogenetic potential of non-genotoxic compounds
[28]. This, in particular, involves GEMs with constitutive
or conditional tissue specific deletion of tumor suppres-
sor genes [29]. We have described a mammary gland
specific dominant negative mutated p53 mouse model,
p53R270H/+WAPCre [30]. The model is based on a point
mutation corresponding to the p53 mutated hotspot
p53.R273H in the human Li Fraumeni cancer syndrome.
Mutant p53 is only expressed when Cre recombinase is in-
duced by the whey acidic protein promoter (WAP) in the
mammary gland. This leads to spontaneous mammary
gland tumor formation initiated within a year.
Here we used the p53R270H/+WAPCre model to evalu-
ate the carcinogenic potential of several insulin (like)
molecules: insulin NPH, insulin glargine, insulin X10
and IGF1. We demonstrated that chronic exposure to
insulin X10 and IGF1 significantly promotes mammary
gland tumor development, while glargine and insulin do
not. Yet, glargine-related tumors do have a different pro-
mitogenic signaling that is distinct from control and in-
sulin treated mice, and more reminiscent of insulin X10
and IGF1.Methods
The p53R270H/+WAPCre mouse model
Heterozygous p53.R270H as well as the WAPCre mice
were backcrossed with FVB mice over 15 times to yield
a >99.99% FVB genetic background. Heterozygous con-
ditional p53.R270H mice, >8-week-old, were crossed to
transgenic WAPCre mice of the same age to generate
p53R270H/+WAPCre mice [30,31]. The mammary gland
specific Cre recombinase splices out the intronic floxed
stop cassette of the p53.R270H allele that eventually
would lead to spontaneous mammary gland tumor for-
mation of one-year-old p53R270H/+WAPCre female mice.
A high expression WAP promoter was used [32], which
is already active in the mammary gland of non-pregnant,
non-lactating virgin mice. Therefore, we used only nul-
liparous mice in this experiment. A PCR/digestion based
assay was used for genotyping using the same primers as
previously described [30] and subsequent restriction
analysis using Hsp92II. The presence of the R270H
mutation leads to digestion of the 486 bp p53 PCR
amplicon into a 269 and 217 bp product. The presence
of Cre recombinase was verified by a 676 bp amplicon
[30]. All mice were fed ad libitum with RM1 diet (SDS,
technilab-BMI, Someren, Holland).
Preparation of insulin, insulin analogues and IGF1
injection solutions
The treatments included: insulin NPH (Insuman Basal,
Sanofi Aventis, Gouda, The Netherlands), insulin glargine
(Lantus, Sanofi Aventis), insulin X10 (AspB10, Novo
Nordisk, Alphen aan den Rijn, The Netherlands) and
IGF1 (Increlex, Ipsen, Hoofddorp, The Netherlands). All
compounds were dissolved in their original vehicle solu-
tions: glargine (glycerol 0.2 mol/L, m-cresol 0.025 mol/L,
ZnCl2 0.0002 mol/L adjusted to pH 4.0), insulin (glycerol
0.2 mol/L, NaH2PO4 0.00135 mol/L, phenol 0.0063 mol/L,
m-cresol 0.0138 mol/L, ZnCl2 0.0001 mol/L adjusted to
pH 7.4), X10 (glycerol 0.2 mol/L, phenol 0.0063 mol/L,
m-cresol 0.0138 mol/L, ZnCl2 0.0001 mol/L adjusted to
pH 7.4) and IGF1 (benzyl alcohol 0.083 mol/L, sodium
chloride 0.1 mol/L, polysorbate 20 0.0016 mol/L, acetic
acid 0.0072 mol/L, sodium acetate 0.05 mol/L adjusted to
pH 5.4).
Experimental set-up
The experimental setup of the studies was examined and
approved by the institute’s Ethical Committee on Animal
Experimentation, in accordance with national and
European legislation.
In a first panel of short term experiments, the maximal
pharmalogical dose (MPD) was determined for each
compound in our mouse model. In a 10 hour experiment
(n = 54) the glucose drop was measured (Freestyle light,
70812–70, Abbott, Olst, The Netherlands) sequentially
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lin NPH, glargine, regular insulin, X10 or IGF1 (Additional
file 1: Figure S1). A wide concentration range based on
the literature was evaluated: insulin NPH and insulin
glargine (25 nmol/kg to 125 nmol/kg); insulin X10
(480 nmol/kg to 1,800 nmol/kg); and IGF1 (5 mg/kg
to 15 mg/kg) [12]. In a subsequent experiment (n =
52) the effects of frequent injections were determined
(Additional file 1: Figure S2). Besides blood glucose
levels, the weight and overall well-being were deter-
mined during one month of daily injections.
Based on the above data, the long-term exposure ex-
periment was designed in which the mice were injected
with 50% and 80% of the MPD according to Additional
file 2: Table S1. Once the female p53R270H/+WAPCre
mice were about eight-weeks old, they were ran-
domly distributed in the dose groups using the pro-
gram ‘randomice’. Mice were weighed every week, and a
standard injection solution per compound/concentration
was made to ensure an injection volume in the range of
60 to 130 uL. To avoid adverse reactions at the injection
site due to frequent injection, three subcutaneous injec-
tion sites were used: neck, upper back and lower back.
Mice were injected every other day for up to 67 weeks
and palpated for tumors twice a week. A typical mam-
mary gland tumor could be detected once it had a volume
of about 8 mm3. Dimensions were noted to monitor tumor
growth. Once the tumor reached a volume of about 1 cm3,
the mouse was sacrificed and dissected. Tumors from
other origins were generally difficult to palpate, so other fit-
ness markers (weight loss, skin condition, motility, and
so on) were used to decide when to sacrifice an animal.
Histopathology and immunofluoresence
When mice were destined for sacrifice based on tumor
size or other markers, they were euthanized one day
after the last injection, blood was collected and serum
was extracted (mini collect, Greiner Bio-one B.V.,
Alphen aan de Rijn, The Netherlands) according to the
manufacturer’s protocol. A quarter of the tumor, liver,
lung, pancreas, kidney and spleen were fixed in a neutral
aqueous phosphate buffered 4% solution of formalde-
hyde (Klinipath/VWR, Duiven, The Netherlands) for
24 hours and stored in 70% EtOH. These tissues were
embedded in paraffin wax, sectioned at 5 μm, and stained
with hematoxylin and eosin (H & E) for histopathologic
evaluation. Immunofluorescence (IF) was performed on
twenty representative tumors (based on the H & E
characterization) from the different tumor types. Citrate
buffer was used for antigen retrieval, blocking was per-
formed in 10% normal goat serum (NGS). Antibodies
were diluted (1:10 to 1:800) in 1% NGS buffer. Antib-
odies used were smooth muscle actin (A2547, Sigma-
Aldrich, Zwijndrecht, The Netherlands), cytokeratin 5(PRB-160P, Covance, BioLegend, London, UK), cytoker-
atin 8 (rdi-pro61038, Fitzgerald/Bioconnect, Huissen,
The Netherlands), E-cadherin (610181, BD Transduc-
tion, Breda, The Netherlands). Fluorescently labelled
secondary antibodies were from Jackson Laboratories,
Suffolk, UK. Images were made on a Nikon Eclipse TS100
microscope. The histopathology was based on analysis of
the macroscopic tumors. The epithelial and mesenchymal
cell distributions were estimated by a pathologist on mor-
phological characteristics of these cell types.
Western blotting
A quarter of the tumor was snap frozen in liquid nitro-
gen, stored at −80°C and used for subsequent protein ex-
pression profiling. A tumor piece was ground and lysed
with 300 μL tumor lysis buffer (20 mM Tris–HCl,
pH 7.4, 137 mM NaCl, 2 mM ethylenediaminetetraacetic
acid (EDTA), 1% Triton, 10% glycerol, 1:100 protease
inhibitor cocktail) for 30 minutes at 4°C. After centrifuga-
tion (10 minutes, 10,000 rpm), supernatant was collected
and the protein concentration was determined (BCA TM
Protein Assay Kit; Thermo Scientific, Rockford, IL, USA).
The Western blotting procedures and all antibodies were
identical to [8]. In addition, antibodies targeting Her2 (Cell
Signaling Technology, Danvers, MA, USA), β-actin,
GAPDH, ER-α and EGFR, (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) were used. The same endogenous
control (EC) sample consisting of a mix of 30 random
mammary gland tumor samples was used on each blot.
Statistical analysis
Statistical analyses of (mammary gland) tumor-free sur-
vival curves included calculation of censored Kaplan-
Meijer distribution of survival of two different treatment
groups and comparison by a two-sided log-rank test
using Graphpad Prism version 4.00 software. The same
software was used to determine P-values over the mean
weight, percent of epithelial cells and average number of
mammary gland tumors using the two-sided t-test. For
the correlation plots linear regression was applied.
Results
Insulin analogue treatment induces a metabolic and, at
high concentrations, a toxic response
We first systematically determined the doses at which
each insulin analogue induced a glucose drop (Additional
file 1: Figure S1). Two hours after the injection the max-
imal (approximately 60%) blood glucose decrease was ob-
served (from approximately 6 to approximately 2 mmol/L)
which was followed by a glucose recovery, depending on
the insulin dose. Mice injected with short-acting insulin
forms (X10 and regular insulin) required more time to re-
cover. Next, a dose dependent positive weight effect was
observed during one month daily treatment for most
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IGF1 caused a weight loss compared to control (Additional
file 1: Figure S2). Despite this evident adverse effect, no
mortality of mice was observed so this dose was referred to
as the MPD.
Insulin X10 and IGF1 treatment of p53R270H/+WAPCre
female mice increases body weight
We then performed a life-long repeated dosing of 10-
week old p53R270H/+WAPCre female mice with all four
insulin analogues as well as the controls. We carefully
monitored the weight until 35 weeks, a point in time at
which the first animals developed mammary tumors
(Figure 1A, top panel). X10 and IGF1 induced the stron-
gest weight gain. In contrast, insulin and glargine did not
affect the weight compared to the vehicle treated animals.Figure 1 Effect of insulin analogues on mammary gland tumor develo
represent the average weight of the mice in the indicated groups during t
with an unpaired t-test. B) Effect of different compounds on mammary gla
analysis for the survival curves was determined with the log rank test.Insulin X10 and IGF1 treatment significantly decreases
the latency time for mammary gland tumor development
Next, we further followed mammary gland tumor forma-
tion. In total, 100% of the mice that remained part of the
experiment developed tumors, 83% of which were mam-
mary gland tumors with an average latency time of
40 weeks (Table 1).
Subcutaneous injections of vehicle 1 and vehicle 2 did
not cause a significant difference in tumor latency time
compared to untreated animals (P = 0.7194, data not
shown) and were further combined in one control
‘vehicle’ group. Subcutaneous injection of the vehicle
did not significantly affect the tumor latency time
compared to untreated animals (P = 0.8476, data not
shown). Each insulin analogue was dosed at 50% and 80%
of the MPD. None of the different compounds showed apment in p53R270H/+WAPCre female mice. A) Upper graphs
he first 35 weeks of the experiment. Statistical analysis was determined
nd tumor free survival shown as in Kaplan Meier curves. Statistical
Table 1 Results overview of p53R270H/+WAPCre model subcutaneously injected with growth factors
Tested variable Insulin Glargine X10 IGF1 Vehicle
Number of mice analyzed 40 40 40 40 38
Mortality 6/40 (15%) 3/40 (8%) 5/40 (13%) 4/40 (10%) 1/38 (3%)
Mean weight of mice (grams)a 30 ± 0.5 30 ± 0.5 32 ± 0.6 34 ± 0.7 29 ± 0.4
P-valueb 0.1996 0.1567 0.0002 <0.0001 NA
Tumor-bearing mice 34/34 (100%) 37/37 (100%) 35/35 (100%) 36/36 (100%) 37/37 (100%)
Mean tumor latency-time (weeks)c 44.9 38.0 37.9 36.0 42.6
P-valued 0.1463 0.1448 0.0707 0.0549 NA
Mammary gland tumor 29/34 (85%) 31/37 (84%) 31/35 (89%) 28/36 (78%) 29/37 (78%)
Carcinocarcoma 24/29 (83%) 25/31 (81%) 26/31 (84%) 25/28 (89%) 23/29 (79%)
EMT status (% epithelial) 20.8 ± 4.89 27.5 ± 4.83 31.2 ± 4.01 18.8 ± 4.71 15.71 ± 3.80
P-valueb 0.2170 0.0672 0.0086 0.6251 NA
Carcinoma 5/29 (17%) 5/31 (16%) 5/31 (16%) 3/28 (11%) 6/29 (21%)
Adenoma 0/29 1/31 (3%) 0/31 0/28 0/29
Mean MG tumor latency-time (weeks)c 45.0 41.9 37.9 38.4 44.9
P-valued 0.8329 0.0688 0.0044 0.0207 NA
Mean MG tumor doubling time (days) 1.75 ± 0.11 1.87 ± 0.21 1.83 ± 0.19 1.53 ± 0.12 1.470 ± 0.14
P-valueb 0.1375 0.1305 0.1632 0.7594 NA
Mice with multiple MG tumors 10/34 (29%) 16/37 (43%) 18/35 (51%) 16/36 (44%) 13/37 (35%)
Average number of MG tumors 1.50 ± 0.16 2.00 ± 0.24 1.82 ± 0.16 2.07 ± 0.23 1.64 ± 0.15
P-valueb 0.5289 0.2371 0.4337 0.1346 NA
aMean weight depicted as average weight of mice from start of injections (mice are ± 8 wks) until mice are sacrificed; bmean latency time is depicted as number
of weeks after start of the subcutaneous injections; cP-values determined by comparing the Kaplan-Meijer curves of compounds with vehicle; dP-values determined by
comparing compounds with vehicle, unpaired t-test. EMT, epithelial to mesenchymal transition; MG, mammary gland.
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gine P = 0.1447, X10 P = 0.1619, IGF1 P = 0.6064; data not
shown). Therefore, we also combined the two dose groups
per compound. The tumor growth rate was next deter-
mined by calculating the tumor doubling time in the expo-
nential part of the Gompertz equation curve as in [33]. All
tumors showed a similar doubling time (1.44 to 1.78
day−1), independent of treatment conditions (Table 1).
The overall mammary gland tumor latency time
(MTLT) for control mice was 44.9 weeks. IGF1 and
insulin X10 caused a significantly decreased mean
MTLT of 6.5 and 7.0 weeks respectively, compared to the
vehicle treatment (Figure 1B; MTLT decreases from
44.9 weeks for control to 38.4 weeks (P = 0.0207) and
37.9 weeks (P = 0.0044) for IGF1 and X10, respectively).
Glargine injections led to a tumor latency time reduction
of three weeks, although this was not significantly different
(P = 0.0688). No effect on MTLT was observed for treat-
ment with human insulin (P = 0.8329). A total of 41% of
the mice developed multiple mammary gland tumors.
Different insulin analogues do not affect mammary gland
tumor type
All mammary proliferative lesions were next classified
according to the criteria described by the AnnapolisPathology Panel (Figure 2A) [34]. Irrespective of treatment
condition, the majority (123/148, 83%) of mammary gland
tumors was diagnosed as EMT (epithelial to mesenchymal
transition) tumor, 16% (24/148) as carcinoma and 1%
(1/148) as adenoma (Table 1).
EMT tumors with a clearly distinguishable histological
epithelial component also showed clear E-cadherin stain-
ing, whereas EMT tumors that predominantly consist of
mesenchymal cells showed high levels of smooth muscle
actin (SMA) (Figure 2B). In total, 31 mice developed other
tumors: ten thymic lymphoma, six lung adenocarcinomas,
and a small number of lymphomas, bone, uterus or pan-
creas tumors (Figure 2C). No correlation between the
prevalence of non-mammary gland tumors and treatment
could be detected. Typically lymphomas developed
significantly earlier (independent of treatment) compared
to mammary gland EMT tumors and carcinomas
(30.8 weeks versus 41.4 and 39.1 weeks, respectively).
There was no clear correlation between treatment and
tumor spectrum (Figure 2D). EMT tumors were previ-
ously described as carcinosarcomas, and these terms can
be used as synonyms [35]. Three-dimensional culturing
of isolated cells from these primary tumors resulted in
an invasive morphology, one of the characteristics of
an EMT tumor (data not shown). The EMT-phenotype
Figure 2 (See legend on next page.)
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Figure 2 Insulin analogues induce primarily EMT tumors in p53R270H/+WAPCre female mice. A) H & E images of representative EMT tumors
with predominantly epithelial cells (left panel) and an EMT tumor with predominantly mesenchymal cells (right panel). B) Immunofluoresent
images of CK5/8, area with normal mammary duct on the same slide that serves as control for CK5/CK8 staining, E-cadherin and smooth muscle
actin. C) Tumor type distribution per treatment. D) Mammary gland tumor type distribution per treatment. E) Average number of mammary
gland tumors. F) Percentage of epithelial cells in the EMT tumors over the different treatment groups. EMT, epithelial to mesenchymal transition.
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presence of epithelial structures displaying loss and disrup-
tion of basement membrane and associated with epithelial-
to-spindle cell morphology transition and gradual blending
or invasion into the surrounding stroma [36]. Most mam-
mary tumors showed invasion of the surrounding fat pad.
Variable-sized intratumoral areas of necrosis were also
present, often accompanied by a desmoplastic reaction and
severe infiltration of inflammatory cells composed mostly
of neutrophils and reactive macrophages.
Some mice developed more than one mammary gland
(MG) tumor. There appears to be a trend in the inci-
dence of increased multiple MG tumors for glargine,
X10 and IGF1, compared to vehicle treatment, but none
of these treatments reached significance (Figure 2E).
We also assessed the percentages of epithelial and
mesenchymal cells. Only X10 treatment induced signifi-
cantly (P = 0.0086) more EMT tumors with a higher epi-
thelial prevalence (Figure 2 F). To further assess the
origin from either the basal or the luminal part of the
MG ducts, the expression of CK5 and CK8 was evalu-
ated, respectively. Based on expert judgment of the path-
ologist we have screened a subset of twenty tumors,
equally distributed over the treatment groups. From
these tumors only one was stained positive for CK5 and
negative for CK8, all other tumors showed clear CK8
staining and lack of CK5 indicating that the majority of
the tumors likely originated from the luminal part of the
MG. A representative immunofluorescent picture of a
luminal tumor and the only basal tumor that we found
can be found in Additional file 1: Figure S3. No correl-
ation was detected between the different treatment con-
ditions or with tumor histology.
Molecular profiling of IR and IGF1R signaling pathways in
insulin analogue induced mammary gland tumors
To further understand the underlying mechanism of the
decreased tumor latency by IGF1 and X10, we deter-
mined the expression of proteins in the main signaling
pathways associated with IR and IGF1R signaling as well
proteins used in breast cancer classification. This in-
cluded the quantitative analysis of IR-β, IGF1R-β, EGFR,
Her2, E-cadherin, N-cadherin, Akt, p-Akt, Erk, p-Erk,
ER-α, tubulin and β-actin protein levels in all primary
mammary gland tumors. A small subset of the Westernblot data (n = 36) is presented in Figure 3A; the quantita-
tive analysis of Figure 3B is based on all Western blots
(n = 148) shown in Additional file 1: Figure S4. Overall,
only IR, IGF1R, p-Erk or p-Akt levels were significantly
affected in insulin analogue treatment-related mammary
tumor (Figure 3B). Interestingly, the IR and IGF1R re-
ceptor levels in tumors of compound treated animals
were all significantly upregulated compared to control.
Importantly, IGF1-dependent tumors not only upregu-
lated IGF1R, but also showed a significant (P = 0.0066)
upregulation of IR; similarly insulin treated mice demon-
strated IR upregulation but also showed significantly
higher (P = 0.0005) IGF1R levels.
Also, phosphorylated Akt was more abundant in tu-
mors of mice treated with insulin-like molecules; espe-
cially insulin, X10 and IGF1 stimulation led to tumors
with very significant higher activation of the PI3K sig-
naling pathway. Interestingly, glargine, X10 and IGF1
but not insulin stimulation led to an increased activa-
tion of the MAPK signaling cascade in the obtained
tumors. This effect was only significant for glargine
(P = 0.0125) and X10 (P = 0.0018) but not for IGF1
(P = 0.0980) when compared to the tumors from the
vehicle-treated mice.
We also compared the association between IR and
IGF1R expression (Figure 3C). Overall there seemed to
be a direct linear correlation between IR and IGF1R,
suggesting interdependency. To evaluate the relation-
ship between IR and IGF1R levels and tumor latency,
we separated the entire group of tumors into five equal
clusters each representing 20% of the tumors based on
right-angled distribution on the linear regression curve.
For each cluster the mean latency time was determined
irrespective of treatment condition (Figure 3D), but
only involving insulin, glargine, X10 and IGF1 condi-
tions. Intriguingly, a long latency time and, thus, a long
exposure to the insulin-like molecules, is associated
with increased insulin- and IGF1-receptor levels. While
the tumors of all control animals showed a strong cor-
relation between IR and IGF1R expression levels, albeit at
a lower expression level (see Additional file 1: Figure S4
and Figure S3B), no correlation was observed with either
latency time or receptor levels. A similar correlation was
observed between IR/p-Akt and IGF1R/p-Akt (data not
shown).
Figure 3 (See legend on next page.)
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Figure 3 Molecular profiling of IR and IGF1R signaling in insulin analogue derived mammary gland tumors. Tumor protein levels of
critical mammary gland tumor related receptors (IR, IGF1R, ER, EGFR, Her2) and downstream signaling pathways (Erk, phospho-Erk, Akt, phospho-Akt) as
well as epithelial differentiation markers (N-cadherin and E-cadherin) were determined by quantitative Western blotting of all primary mammary gland
tumors (n = 148). A) A small subset of the Western blot data (n = 36) is shown which are representative for the quality of the blots. B) The quantitative
IR, IGF1R, p-Akt and p-Erk levels of all primary EMT tumors are presented in dot-plots (n = 148). C) The IR versus IGF1R protein levels are plotted,
five clusters are defined. D) The mean tumor latency time has been determined of each cluster. Error bars represent SEM, ns = P >0.05, * = P <0.05,
** = P <0.01, *** = P <0.001. EGFR, epidermal growth factor receptor; EMT, epithelial to mesenchymal transition; ER, estrogen receptor; IGF1R, insulin-like
growth factor 1 receptor; IR, insulin receptor; SEM, standard error of the mean.
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enhanced Erk and Akt activity
Since the insulin analogue treatment apparently affected
and directed the composition and the activity of signaling
machinery in the MG tumors, we next determined whether
specific subgroups of profiles existed and whether these
would cluster with particular insulin analogues. We
focused on those signaling components that were sig-
nificantly different between control and insulin-like
molecule treatment (that is, IR, IGF1R, p-Erk and p-Akt)
and evaluated all EMT tumors (n = 123; the major
tumor type irrespective of treatment condition), thereby
eliminating tumor type variation. Hierarchical clustering
of the quantitative signaling data separated in nine
clusters (Figure 4A and B). Five clusters showed in-
creased p-Erk level as a dominating signaling pathway:
clusters 1, 5 and 7 represented high p-Erk which was
dominated by IGF1, X10 and glargine related EMT tu-
mors (together 78%, n = 22 tumors); clusters 2 and 8
showed lower p-Erk with no clear enrichment (n = 15
tumors). In addition, two clusters especially represented
Akt activation: clusters 5 and 6 preferentially showed
high p-Akt activity, and together these clusters demon-
strated enrichment for IGF1 and X10 treatment (75%;
n = 16 tumors). Importantly, there were no tumors from
the control group that showed high p-Akt levels. Two
large clusters (4 and 9) did not show any dominance or
activation of either Erk or Akt; in these two clusters
there was a slight overrepresentation of control and in-
sulin treatment (61%; n = 31 tumors). These combined
data suggest that pro-mitogenic insulin analogues drive
tumor formation that is dominated by either p-Erk
and/or p-Akt, although at this point we cannot exclude
the activation of additional signaling pathways. We also
determined the tumor latency time for each cluster
(Figure 4C). Overall, clusters enriched for pro-mitogenic
insulin analogues and associated enhanced mitogenic sig-
naling, either Erk or Akt, did not significantly correlate
with latency time. Yet, a tendency existed for a shorter la-
tency time in cluster 1 which had the highest p-Erk level.
Therefore, we also determined the correlation between
either p-Erk or p-Akt status for any treatment condition
and MG tumor latency time (Figure 4D and E). A signifi-
cant negative correlation was found between p-Erk statusand latency time. This effect was strongest for IGF1-
induced tumors, but glargine-induced tumors also
showed this trend. A weak non-significant positive cor-
relation was found between p-Akt status and EMT tumor
latency time. Interestingly, this positive effect was ob-
served for all treatments, except for the control group.
Discussion
In the present study, we used the p53R270H/+WAPCre
mouse model to assess the carcinogenic potential of two
insulin-like molecules, X10 (AspB10) and glargine in dir-
ect comparison to insulin NPH and IGF1. Our data indi-
cate that the highly mitogenic compounds, insulin X10
and IGF1, which both stimulate the IGF1-receptor, sig-
nificantly decreased the latency time for tumor develop-
ment. This was not observed for glargine and insulin
NPH. Moreover, we demonstrated that tumors derived
after mitogenic insulin analogue treatment induce mam-
mary gland tumors with enhanced intracellular signaling
through either the Erk or Akt pathway, which was not
observed in control animals. Our data indicate that the
p53R270H/+WAPCre mouse model is sensitive to evaluate
the intrinsic higher mitogenic potential of insulin-like
compounds and the associated contribution to cancer
development. Interestingly, while this mouse tumor
model largely gives rise to EMT mammary gland tumors
irrespective of insulin treatment conditions, the mito-
genic insulin-like molecules drive the formation of tu-
mors with enhanced key mitogenic signaling activity.
X10 as well as IGF1 significantly decreased tumor la-
tency time. These two compounds also induced a signifi-
cant weight increase. However, there is no overall
correlation between tumor latency time and mouse
weight at tumor detection date (Additional file 1:
Figure S5), indicating that chronic treatment of X10
and IGF1 affects tumor latency directly by mitogenic
signaling rather than indirectly by obesity.
Similar to insulin NPH, chronic exposure to insulin
glargine did not significantly affect tumor latency time
compared to the vehicle treatment, although tumors de-
veloped slightly earlier in the glargine treated animals.
These glargine data are in line with a previous report by
Stammberger et al. in which a lifelong exposure of glar-
gine did not show any difference in the incidence of
Figure 4 (See legend on next page.)
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Figure 4 Hierarchical clustering of insulin (analogue) tumors based on IR and IGF1R signaling components. Quantitative expression levels
of IGF1R-β, IR-β, p-Akt and p-Erk in mammary gland EMT tumors of all treatment groups were clustered using Euclidean distance and average
linkage (A). Distinct clusters appeared in which the treatment groups are not equally distributed. In protein clusters 1, 2, 5 and 6, the highly
mitogenic treatment groups (IGF1 and X10) are overrepresented. In graphs B and C the distribution of several parameters of the clusters are
shown. B) Treatment group distribution. C) Latency time per cluster, in which it became apparent that the cluster with the highest p-Erk levels
has the shortest tumor latency time. In the last two graphs the correlation between latency time and p-Erk (D) or latency time and p-Akt (E) is
presented. Interestingly, high p-Akt levels are positively correlated with latency time, but only in the compound treatment groups and not in the
vehicle treated animals. EMT, epithelial to mesenchymal transition; IGF1R, insulin-like growth factor 1 receptor; IR, insulin receptor.
ter Braak et al. Breast Cancer Research  (2015) 17:14 Page 11 of 13mammary tumors reported in both mice and rats when
comparing with the NaCl, vehicle-control, or the NPH
insulin treated groups in wild type mice and rats [13].
When conducting a pathology study on the different tu-
mors, we found no difference between insulin NPH ver-
sus glargine induced tumors. These histopathology
results are in agreement with a study performed by Besic
et al., in which a clinical and histopathological screening
was performed on breast carcinomas of diabetic patients
who were either on a glargine or other insulin (analogue)
therapy [37].
We previously showed in in vitro models that insulin
IGF1, X10 and glargine can strongly activate the IGF1R-
mediated signaling, but that only IGF1 and X10 have an
increased mitogenic potential [8]. Insulin glargine did
not significantly enhance cell proliferation, which was
largely explained by the rapid metabolism of glargine,
preventing a sustained activation of IGF1R-mediated
mitogenic signaling [8]. These insulin-like compounds
have been tested for carcinogenic side-effects in wild
type mice and rats [10,11,38], but to our knowledge
they have never been tested in sensitive humanized
in vivo models. Our current in vivo findings are in
agreement with these in vitro observations. Yet, des-
pite the fact that insulin glargine did not significantly
enhance MG tumor development, many insulin glar-
gine tumors also demonstrated enhanced Erk and Akt
activity, which was hardly observed under control con-
ditions. This suggests that insulin glargine is not inert
and may affect the intracellular signaling in the devel-
oping tumor.
The majority of the obtained tumors in our
p53R270H/+WAPCre mouse model were classified as
EMT tumors; these tumors are thought to be in the
epithelial to mesenchymal transition state. This type
of MG tumor is not a commonly found human breast
cancer subtype. Nevertheless, as in human breast cancer,
the intracellular signaling varied considerably between
the various tumors. In particular, a strong enhancement
of Erk and Akt activity was evident in the mitogenic
insulin-like molecules groups, which was hardly observed
for untreated mice. This variation induced by our insulin
treatment conditions probably provides a better repre-
sentation of human breast cancer in general and EMTtumors in particular. Hence, a mitogenic treatment set-
ting might provide enhanced information on human
breast cancer development. Yet, given the biased forma-
tion of EMT tumors in the current study setup, further
carcinogenic studies with insulin-like molecules are
required with other humanized mouse MG tumor models.
This could involve genetically engineered mouse models
(GEMMs) with a human specific mutation in, for example,
the PI3K signaling pathway [39].
Long-term administration of IGF1, X10, glargine and
insulin led to tumors with significantly higher p-Akt
levels compared to vehicle treated animals. This indi-
cates that the PI3K signaling cascade is up regulated
upon stimulation with the insulin-like molecules. Simi-
larly the MAPK signaling pathway was up regulated after
IGF1, X10 and glargine treatment. Interestingly, long-
term stimulation with insulin did not affect the p-Erk1/2
levels in the obtained tumors.
At this moment we do not know the exact mechanism
by which the more mitogenic insulin like molecules
promotes MG tumor development. Since Erk and Akt
activity did not per se coincide in the various tumors
and/or relate to enhanced IGF1R levels, direct ligand-
mediated activation of the Erk and Akt pathways seems
unlikely. Possibly, mutations in either Erk and/or Akt
pathway components are underlying the enhanced acti-
vation of these signaling molecules. In such a scenario,
activation of the IGF1R and/or IR may promote the
selection of the initiated cells that have incorporated
mutations in Erk/Akt pathway components (for ex-
ample, Ras or PI3K). This could provide a suggestion
that treatment with human insulin analogues may initi-
ate the development of mammary tumors with an
altered mutational and/or signaling spectrum. More in-
depth molecular analysis of the mouse tumors at the
genome and proteome level is needed to further under-
stand the underlying mechanism for the enhanced
tumor formation by the IGF1 and X10 treatment con-
ditions and their potential role in either enhanced
tumor initation and/or progression. While we studied
the effect of insulin analogues on MG tumor develop-
ment, we cannot exclude that insulin analogues with
high affinity for the IGF1R may also promote breast
cancer progression, either locally or at distant sites, or
ter Braak et al. Breast Cancer Research  (2015) 17:14 Page 12 of 13modulate sensitivity to anticancer drugs. This needs
further investigation and our different mouse MG
tumor banks that show different expression levels of
IGF1R and IR could contribute to this.Conclusions
The p53R270H/+WAPCre mouse model is a sensitive and
human relevant model to test the carcinogenic proper-
ties of insulin-like molecules, as is apparent with insulin
X10 and IGF1. Insulin glargine was tested in this study
and did not show a significantly decreased tumor latency
time compared to insulin NPH, although the MAPK-
signaling pathway was upregulated as found for X10 and
IGF1. As is the case in humans, rapid conversion of glar-
gine into metabolically active metabolites M1 (and to a
lesser extent M2) is likely to be the reason for the low
carcinogenic potential of subcutaneous injected glargine.
All in all, based on the current tumor model, the data
suggest that glargine users are not facing an increased
carcinogenic hazard compared to insulin NPH users.
Yet, future studies in mouse models that lead to more
human relevant tumors remain important to fully ex-
clude a role for current clinically relevant insulin analo-
ques in the development and/or progression of human
breast cancer.Additional files
Additional file 1: Figure S1. Blood glucose levels measured in
p53R270H/+WAPCre mice after injections with a concentration range of
insulin(−like) molecules. A) insulin NPH injections, B) glargine injection,
C) IGF1 injections, D) regular human insulin injections and E) X10
injections. The number 1 graphs represent the blood glucose levels of
injected mice over time. The number 2 bar plots represent the area
above the curve of the first blood glucose drop (first three hours).
Each data point represents the average blood glucose levels of two
mice. Figure S2. Weight measured in p53R270H/+WAPCre mice after
injections with a concentration range of insulin(−like) molecules. A) Insulin
NPH injections, B) glargine injection, C) IGF1 injections, D) regular human
insulin injections and E) X10 injections. The number 1 graphs represent the
weight increase in % of injected mice over time. The number 2 bar plots
represent the area under the curve of the weight increase plots. Figure S3.
Origin of tumors. Representative EMT tumor originating from myo-epithelial
part (first IF image which is CK5+) or luminal part (second IF image
which is CK8+) of mammary gland (MG) (n = 19). Figure S4. Protein
expression profiles of all primary mammary gland tumors. Tumor protein
levels of critical mammary gland tumor-related receptors (IR, IGF1R, ER,
EGFR, Her2) and downstream signaling pathways (Erk, phospho-Erk, Akt,
phosphor-Akt) as well as epithelial differentiation markers (N-cadherin and
E-cadherin) were determined by quantitative Western blotting of all
primary mammary gland tumors (n = 148). EC is the endogenous
control, a sample that was loaded on every blot to correct for blot specific
effects. Figure S5. No correlation between tumor latency time and weight
of mice at tumor detection date. (P = 0.8939, best fit linear slope −0.022).
Additional file 2: Table S1. Set-up of long-term exposure experiment.
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